Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

A sickle cell gene therapy treatment has allowed a Long Island man to turn a chapter in his life, with doctors declaring him ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Scientists have discovered more than a dozen genes that regulate the production of fetal hemoglobin in people of African ...

People with inflammatory bowel disease (IBD) also have an increased risk of developing colorectal cancer. However, the exact ...

A breakthrough in safely delivering therapeutic DNA to cells could transform treatment for millions suffering from common ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...

Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.